Altimmune Q3 net loss $23.5M, cash $201.9M; pemvidutide NAFLD data mid-Dec, obesity interim Q1 2023

Altimmune, Inc.

2022-Q3 EPS reported -$1.37 revenue$42,000

Net loss of $23.5M ($0.48 per share) vs $33.5M loss YoY; revenue minimal at ~$0.
Cash, equivalents & short-term investments totaled $201.9M at September 30, 2022.
Topline 24-week data from Phase 1b NAFLD trial expected mid-December 2022.
Interim 24-week readout from Phase 2 MOMENTUM obesity trial (~160 subjects) expected Q1 2023.
Enrollment complete in Phase 1b type 2 diabetes trial; data readout expected Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Altimmune, Inc. reported financial results for three months ended September 30, 2022.

Period: three months ended September 30, 2022
Result: reported results

Exact text from the filing

Revenue was minimal for the three months ended September 30, 2022 compared to $0.2 million in the same period in 2021.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-22-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.